Qingyang Ma

Suzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial.

Journal: JAMA
Published: June 07, 2026

Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial.

Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m2 but without diabetes: A phase 2 randomized controlled trial.

Journal: Med (New York, N.Y.)
Published: August 13, 2025

Mazdutide versus placebo in Chinese adults with type 2 diabetes.

Mazdutide versus placebo in Chinese adults with type 2 diabetes.

Journal: Nature
Published: June 16, 2025

Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.

Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.

Journal: Nature
Published: June 16, 2025

Fabrication of Hierarchical Assemblies through Temperature-Triggered Liquid Crystallization Driven Self-Assembly.

Fabrication of Hierarchical Assemblies through Temperature-Triggered Liquid Crystallization Driven Self-Assembly.

Journal: Small methods
Published: November 03, 2023

Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

Journal: Diabetes care
Published: July 12, 2023

Pharmacokinetic/LDL-C and exposure-response analysis of tafolecimab in Chinese hypercholesterolemia patients: Results from phase I, II, and III studies.

Pharmacokinetic/LDL-C and exposure-response analysis of tafolecimab in Chinese hypercholesterolemia patients: Results from phase I, II, and III studies.

Journal: Clinical and translational science
Published: July 03, 2023

Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study.

Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study.

Journal: Expert opinion on investigational drugs
Published: June 26, 2023

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.

A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.

Journal: Nature communications
Published: May 29, 2023

Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).

Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).

Journal: BMC medicine
Published: October 09, 2022

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.

Journal: EClinicalMedicine
Published: August 08, 2022

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.

A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.

Journal: Nature communications
Published: December 16, 2021
Showing 1-12 of 14

Last Updated: 09/26/2026